Stéphane Chevaliez1, Dominique Challine2, Habiba Naija3, Tony C Luu4, Syria Laperche5, Lourdes Nadala4, Jean-Pierre Allain6, Helen H Lee7, Jean-Michel Pawlotsky2. 1. National Reference Center for Viral Hepatitis B, C and Delta, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France; INSERM U955, Créteil, France. Electronic address: stephane.chevaliez@hmn.aphp.fr. 2. National Reference Center for Viral Hepatitis B, C and Delta, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France; INSERM U955, Créteil, France. 3. National Reference Center for Viral Hepatitis B, C and Delta, Department of Virology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France. 4. Diagnostics for the Real World Ltd., Sunnyvale, CA, United States of America. 5. National Reference Center for Viral Hepatitis B, C and Delta in Blood Transfusion, Institut National de la Transfusion Sanguine, Paris, France. 6. Division of Transfusion Medicine, Department of Hematology, University of Cambridge, Cambridge, United Kingdom. 7. Diagnostics for the Real World Ltd., Sunnyvale, CA, United States of America; Diagnostics Development Unit, Department of Hematology, University of Cambridge, Cambridge, United Kingdom.
Abstract
BACKGROUND: Rapid diagnostic tests (RDT) have been developed for the detection of hepatitis B surface antigen (HBsAg). They represent a promising alternative to enzyme immunoassays and a powerful tool for large-scale screening and diagnosis of HBV infection, especially in regions without easy access to serological and molecular testing. OBJECTIVES: The aims of the present study were to evaluate the characteristics and clinical performance of a new CE-marked HBsAg RDT, DRW-HBsAg v2.0 assay (Diagnostics for the Real World™, Ltd., USA), in various patient populations, including those chronically infected with HBV, patients with severe acute hepatitis of unknown origin and pregnant women with unknown HBV serological status at delivery. RESULTS: The lower limit of detection of the assay, evaluated in 21 clinical samples, ranged from 0.30 ± 0.07 to 0.97 ± 0.26 international units/mL (using Abbott Architect as a reference), depending on the HBV genotype. The assay tested positive in 100% of patients with chronic hepatitis B, 96.3% of HBsAg-positive acute hepatitis patients, and 95.2% of HBsAg-positive pregnant women. Its specificity was 98.8% in HBsAg-negative patients, 98.7% in HBsAg-negative patients with acute hepatitis of unknown origin and 97.8% in HBsAg-negative pregnant women. Amino acid substitutions in the HBsAg major hydrophilic region did not affect HBsAg detection by DRW-HBsAg v2.0. CONCLUSIONS: The new DRW-HBsAg v2.0 assay is a simple, rapid, easy-to-run and highly sensitive assay that can be used in both high- and low-risk populations for the diagnosis of HBsAg carriage. It appears to be a promising new tool for large-scale screening and diagnosis of HBV infection.
BACKGROUND: Rapid diagnostic tests (RDT) have been developed for the detection of hepatitis B surface antigen (HBsAg). They represent a promising alternative to enzyme immunoassays and a powerful tool for large-scale screening and diagnosis of HBV infection, especially in regions without easy access to serological and molecular testing. OBJECTIVES: The aims of the present study were to evaluate the characteristics and clinical performance of a new CE-marked HBsAg RDT, DRW-HBsAg v2.0 assay (Diagnostics for the Real World™, Ltd., USA), in various patient populations, including those chronically infected with HBV, patients with severe acute hepatitis of unknown origin and pregnant women with unknown HBV serological status at delivery. RESULTS: The lower limit of detection of the assay, evaluated in 21 clinical samples, ranged from 0.30 ± 0.07 to 0.97 ± 0.26 international units/mL (using Abbott Architect as a reference), depending on the HBV genotype. The assay tested positive in 100% of patients with chronic hepatitis B, 96.3% of HBsAg-positive acute hepatitispatients, and 95.2% of HBsAg-positive pregnant women. Its specificity was 98.8% in HBsAg-negative patients, 98.7% in HBsAg-negative patients with acute hepatitis of unknown origin and 97.8% in HBsAg-negative pregnant women. Amino acid substitutions in the HBsAg major hydrophilic region did not affect HBsAg detection by DRW-HBsAg v2.0. CONCLUSIONS: The new DRW-HBsAg v2.0 assay is a simple, rapid, easy-to-run and highly sensitive assay that can be used in both high- and low-risk populations for the diagnosis of HBsAg carriage. It appears to be a promising new tool for large-scale screening and diagnosis of HBV infection.
Authors: Helena Medina Cruz; Leticia de Paula Scalioni; Vanessa Salete de Paula; Elisangela Ferreira da Silva; Kycia Maria Rodrigues do Ó; Flavio Augusto Pádua Milagres; Marcelo Santos Cruz; Francisco Inácio Bastos; Priscila Pollo-Flores; Erotildes Leal; Ana Rita Coimbra Motta-Castro; José Henrique Pilotto; Lia Laura Lewis-Ximenez; Elisabeth Lampe; Livia Melo Villar Journal: BMC Infect Dis Date: 2015-11-30 Impact factor: 3.090
Authors: Ali Amini; Olivia Varsaneux; Helen Kelly; Weiming Tang; Wen Chen; Debrah I Boeras; Jane Falconer; Joseph D Tucker; Roger Chou; Azumi Ishizaki; Philippa Easterbrook; Rosanna W Peeling Journal: BMC Infect Dis Date: 2017-11-01 Impact factor: 3.090
Authors: James S Leathers; M Belen Pisano; Viviana Re; Gertine Van Oord; Amir Sultan; Andre Boonstra; Jose D Debes Journal: Ann Glob Health Date: 2019-07-04 Impact factor: 2.462